AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
DETECTION OF HUMAN-HERPESVIRUS-8 IN PERIPHERAL-BLOOD OF INDIVIDUALS WITH AND WITHOUT KAPOSIS-SARCOMA, ASSOCIATION WITH CD4 COUNT AND HIV RNA LEVELS
Authors: MIN J KATZENSTEIN D
Citation: J. Min et D. Katzenstein, DETECTION OF HUMAN-HERPESVIRUS-8 IN PERIPHERAL-BLOOD OF INDIVIDUALS WITH AND WITHOUT KAPOSIS-SARCOMA, ASSOCIATION WITH CD4 COUNT AND HIV RNA LEVELS, Journal of investigative medicine, 46(1), 1998, pp. 78-78
GEOGRAPHIC AND DEMOGRAPHIC DIFFERENCES IN THE FREQUENCY OF HUMAN CYTOMEGALOVIRUS GB GENOTYPES 1-4 IN IMMUNOCOMPROMISED PATIENTS
Authors: ZIPETO D HONG C GERNA G ZAVATTONI M KATZENSTEIN D MERIGAN TC RASMUSSEN L
Citation: D. Zipeto et al., GEOGRAPHIC AND DEMOGRAPHIC DIFFERENCES IN THE FREQUENCY OF HUMAN CYTOMEGALOVIRUS GB GENOTYPES 1-4 IN IMMUNOCOMPROMISED PATIENTS, AIDS research and human retroviruses, 14(6), 1998, pp. 533-536
SEXUAL-BEHAVIOR AND RISK ASSESSMENT OF HIV SEROCONVERTORS AMONG URBANMALE FACTORY-WORKERS IN ZIMBABWE
Authors: RAY S LATIF A MACHEKANO R KATZENSTEIN D
Citation: S. Ray et al., SEXUAL-BEHAVIOR AND RISK ASSESSMENT OF HIV SEROCONVERTORS AMONG URBANMALE FACTORY-WORKERS IN ZIMBABWE, Social science & medicine (1982), 47(10), 1998, pp. 1431-1443
CHARACTERIZING PATTERNS OF DRUG-TAKING BEHAVIOR WITH A MULTIPLE-DRUG REGIMEN IN AN AIDS CLINICAL-TRIAL
Authors: KASTRISSIOS H SUAREZ JR KATZENSTEIN D GIRARD P SHEINER LB BLASCHKE TF
Citation: H. Kastrissios et al., CHARACTERIZING PATTERNS OF DRUG-TAKING BEHAVIOR WITH A MULTIPLE-DRUG REGIMEN IN AN AIDS CLINICAL-TRIAL, AIDS, 12(17), 1998, pp. 2295-2303
THE EXTENT OF NONADHERENCE IN A LARGE AIDS CLINICAL-TRIAL USING PLASMA DIDEOXYNUCLEOSIDE CONCENTRATIONS AS A MARKER
Authors: KASTRISSIOS H SUAREZ JR HAMMER S KATZENSTEIN D BLASCHKE TF
Citation: H. Kastrissios et al., THE EXTENT OF NONADHERENCE IN A LARGE AIDS CLINICAL-TRIAL USING PLASMA DIDEOXYNUCLEOSIDE CONCENTRATIONS AS A MARKER, AIDS, 12(17), 1998, pp. 2305-2311
RISK-FACTORS FOR HIV SEROPOSITIVITY AMONG FIRST-TIME BLOOD-DONORS IN ZIMBABWE
Authors: MCFARLAND W MVERE D SHAMU R KATZENSTEIN D
Citation: W. Mcfarland et al., RISK-FACTORS FOR HIV SEROPOSITIVITY AMONG FIRST-TIME BLOOD-DONORS IN ZIMBABWE, Transfusion, 38(3), 1998, pp. 279-284
HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 POPULATIONS IN BLOOD AND SEMEN
Authors: DELWART EL MULLINS JI GUPTA P LEARN GH HOLODNIY M KATZENSTEIN D WALKER BD SINGH MK
Citation: El. Delwart et al., HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 POPULATIONS IN BLOOD AND SEMEN, Journal of virology, 72(1), 1998, pp. 617-623
MORTALITY IN THE FIRST 2 YEARS AMONG INFANTS BORN TO HUMAN IMMUNODEFICIENCY VIRUS-INFECTED WOMEN IN HARARE, ZIMBABWE
Authors: ZIJENAH L MBIZVO MT KASULE J NATHOO K MUNJOMA M MAHOMED K MALDONADO Y MADZIME S KATZENSTEIN D
Citation: L. Zijenah et al., MORTALITY IN THE FIRST 2 YEARS AMONG INFANTS BORN TO HUMAN IMMUNODEFICIENCY VIRUS-INFECTED WOMEN IN HARARE, ZIMBABWE, The Journal of infectious diseases, 178(1), 1998, pp. 109-113
HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA SHEDDING IN THE FEMALE GENITAL-TRACT
Authors: GOULSTON C MCFARLAND W KATZENSTEIN D
Citation: C. Goulston et al., HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA SHEDDING IN THE FEMALE GENITAL-TRACT, The Journal of infectious diseases, 177(4), 1998, pp. 1100-1103
ASSOCIATION BETWEEN HUMAN-IMMUNODEFICIENCY-VIRUS AND HERPES-SIMPLEX VIRUS TYPE-2 SEROPOSITIVITY AMONG MALE FACTORY-WORKERS IN ZIMBABWE
Authors: GWANZURA L MCFARLAND W ALEXANDER D BURKE RL KATZENSTEIN D
Citation: L. Gwanzura et al., ASSOCIATION BETWEEN HUMAN-IMMUNODEFICIENCY-VIRUS AND HERPES-SIMPLEX VIRUS TYPE-2 SEROPOSITIVITY AMONG MALE FACTORY-WORKERS IN ZIMBABWE, The Journal of infectious diseases, 177(2), 1998, pp. 481-484
EFFECT OF THERAPEUTIC IMMUNIZATION WITH RECOMBINANT GP160 HIV-1 VACCINE ON HIV-1 PROVIRAL DNA AND PLASMA RNA - RELATIONSHIP TO CELLULAR IMMUNE-RESPONSES
Authors: KUNDU SK KATZENSTEIN D VALENTINE FT SPINO C EFRON B MERIGAN TC
Citation: Sk. Kundu et al., EFFECT OF THERAPEUTIC IMMUNIZATION WITH RECOMBINANT GP160 HIV-1 VACCINE ON HIV-1 PROVIRAL DNA AND PLASMA RNA - RELATIONSHIP TO CELLULAR IMMUNE-RESPONSES, Journal of acquired immune deficiency syndromes and human retrovirology, 15(4), 1997, pp. 269-274
MEASURING QUALITY-OF-LIFE IN EARLY HIV DISEASE - THE MODULAR APPROACH
Authors: LENDERKING WR TESTA MA KATZENSTEIN D HAMMER S
Citation: Wr. Lenderking et al., MEASURING QUALITY-OF-LIFE IN EARLY HIV DISEASE - THE MODULAR APPROACH, Quality of life research, 6(6), 1997, pp. 515-530
RISK-FACTORS FOR PREVALENT AND INCIDENT HIV-INFECTION IN A COHORT OF VOLUNTEER BLOOD-DONORS IN HARARE, ZIMBABWE - IMPLICATIONS FOR BLOOD SAFETY
Authors: MCFARLAND W MVERE D KATZENSTEIN D
Citation: W. Mcfarland et al., RISK-FACTORS FOR PREVALENT AND INCIDENT HIV-INFECTION IN A COHORT OF VOLUNTEER BLOOD-DONORS IN HARARE, ZIMBABWE - IMPLICATIONS FOR BLOOD SAFETY, AIDS, 11, 1997, pp. 97-102
COMBINATION THERAPIES FOR HIV-INFECTION AND GENOMIC DRUG-RESISTANCE (VOL 350, PG 970, 1997)
Authors: KATZENSTEIN D
Citation: D. Katzenstein, COMBINATION THERAPIES FOR HIV-INFECTION AND GENOMIC DRUG-RESISTANCE (VOL 350, PG 970, 1997), Lancet, 350(9092), 1997, pp. 1712-1712
COMBINATION THERAPIES FOR HIV-INFECTION AND GENOMIC DRUG-RESISTANCE
Authors: KATZENSTEIN D
Citation: D. Katzenstein, COMBINATION THERAPIES FOR HIV-INFECTION AND GENOMIC DRUG-RESISTANCE, Lancet, 350(9083), 1997, pp. 970-971
VIRAL LOAD AND COMBINATION THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS
Authors: KATZENSTEIN D
Citation: D. Katzenstein, VIRAL LOAD AND COMBINATION THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS, The New England journal of medicine, 336(13), 1997, pp. 961-961
HIV SEROINCIDENCE AND CORRELATES OF SEROCONVERSION IN A COHORT OF MALE FACTORY-WORKERS IN HARARE, ZIMBABWE
Authors: MBIZVO MT MACHEKANO R MCFARLAND W RAY S BASSETT M LATIF A KATZENSTEIN D
Citation: Mt. Mbizvo et al., HIV SEROINCIDENCE AND CORRELATES OF SEROCONVERSION IN A COHORT OF MALE FACTORY-WORKERS IN HARARE, ZIMBABWE, AIDS, 10(8), 1996, pp. 895-901
EVALUATION OF A QUALITY ASSURANCE PROGRAM FOR QUANTITATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA BY THE AIDS CLINICAL-TRIALSGROUP VIROLOGY LABORATORIES
Authors: YENLIEBERMAN B BRAMBILLA D JACKSON B BREMER J COOMBS R CRONIN M HERMAN S KATZENSTEIN D LEUNG S LIN HJ PALUMBO P RASHEED S TODD J VAHEY M REICHELDERFER P
Citation: B. Yenlieberman et al., EVALUATION OF A QUALITY ASSURANCE PROGRAM FOR QUANTITATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA BY THE AIDS CLINICAL-TRIALSGROUP VIROLOGY LABORATORIES, Journal of clinical microbiology, 34(11), 1996, pp. 2695-2701
HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE CODON-215 MUTATIONS DIMINISH VIROLOGICAL RESPONSE TO DIDANOSINE-ZIDOVUDINE THERAPY IN SUBJECTS WITH NON-SYNCYTIUM-INDUCING PHENOTYPE
Authors: HOLODNIY M KATZENSTEIN D MOLE L WINTERS M MERIGAN T
Citation: M. Holodniy et al., HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE CODON-215 MUTATIONS DIMINISH VIROLOGICAL RESPONSE TO DIDANOSINE-ZIDOVUDINE THERAPY IN SUBJECTS WITH NON-SYNCYTIUM-INDUCING PHENOTYPE, The Journal of infectious diseases, 174(4), 1996, pp. 854-857
HUMAN-IMMUNODEFICIENCY-VIRUS IN PLASMA AND GENITAL SECRETIONS DURING THE MENSTRUAL-CYCLE
Authors: GOULSTON C STEVENS E GALLO D MULLINS JI HANSON CV KATZENSTEIN D
Citation: C. Goulston et al., HUMAN-IMMUNODEFICIENCY-VIRUS IN PLASMA AND GENITAL SECRETIONS DURING THE MENSTRUAL-CYCLE, The Journal of infectious diseases, 174(4), 1996, pp. 858-861
A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE IMMUNOGENICITY OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) RGP160 VACCINE IN HIV-INFECTED SUBJECTS WITH GREATER-THAN-OR-EQUAL-TO-400 MM(3) CD4 T-LYMPHOCYTES (AIDS CLINICAL-TRIALS GROUP PROTOCOL-137)/
Authors: VALENTINE FT KUNDU S HASLETT PAJ KATZENSTEIN D BECKETT L SPINO C BORUCKI M VASQUEZ M SMITH G KORVICK J KAGAN J MERIGAN TC
Citation: Ft. Valentine et al., A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE IMMUNOGENICITY OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) RGP160 VACCINE IN HIV-INFECTED SUBJECTS WITH GREATER-THAN-OR-EQUAL-TO-400 MM(3) CD4 T-LYMPHOCYTES (AIDS CLINICAL-TRIALS GROUP PROTOCOL-137)/, The Journal of infectious diseases, 173(6), 1996, pp. 1336-1346
THERAPEUTIC SIGNIFICANCE OF SWITCHING TO DIDANOSINE (DDI) OR ADDING DDI IN SUBJECTS WITH ZIDOVUIDINE-RESISTANT HIV-1
Authors: CAVERT W COOMBS RW GRIMES J KURITZKES D JOHNSON V KAPPES J STEIN D BEATTY C ERICE A WINTERS M KATZENSTEIN D JOHNSON E ROJO E MIRABILE M ELBEIK T TSIATIS B COREY L
Citation: W. Cavert et al., THERAPEUTIC SIGNIFICANCE OF SWITCHING TO DIDANOSINE (DDI) OR ADDING DDI IN SUBJECTS WITH ZIDOVUIDINE-RESISTANT HIV-1, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 41-41
SAFETY, PHARMACOKINETICS, AND ANTIVIRAL RESPONSE OF CD4-IMMUNOGLOBULIN-G BY INTRAVENOUS BOLUS IN AIDS AND AIDS-RELATED COMPLEX
Authors: COLLIER AC COOMBS RW KATZENSTEIN D HOLODNIY M GIBSON J MORDENTI J IZU AE DULIEGE AM AMMANN AJ MERIGAN T COREY L
Citation: Ac. Collier et al., SAFETY, PHARMACOKINETICS, AND ANTIVIRAL RESPONSE OF CD4-IMMUNOGLOBULIN-G BY INTRAVENOUS BOLUS IN AIDS AND AIDS-RELATED COMPLEX, Journal of acquired immune deficiency syndromes and human retrovirology, 10(2), 1995, pp. 150-156
ZIDOVUDINE COMPARED WITH DIDANOSINE IN PATIENTS WITH ADVANCED HIV TYPE-1 INFECTION AND LITTLE OR NO PREVIOUS EXPERIENCE WITH ZIDOVUDINE
Authors: DOLIN R AMATO DA FISCHL MA PETTINELLI C BELTANGADY M LIOU SH BROWN MJ CROSS AP HIRSCH MS HARDY WD MILDVAN D BLAIR DC POWDERLY WG PARA MF FIFE KH STEIGBIGEL RT SMALDONE L CRUMPACKER CS COOLEY T MITSUYASO RT JOHN R SANDERS C REITMAN D HEWITT R REICHMAN RC GELB LD MCGUIRE ML JONES M NEIDIG JL ZWICKL B HARTMAN PB ROARKE ME BURK RA FUHRER J SOMOGYI KA SEPKOWITZ K TELZAK EE MCAULIFFE VJ VALENTINE FT VASQUEZ M MERIGAN TC KATZENSTEIN D FESSELL J HAVLIR DV RICHMAN DD SPECTOR SA KAHN JO JOHNSON L COLEMAN R HO M MCMAHON D PAZIN G ANTONISKIS D MCNAMARA B DIAMOND D COLLIER AC PARADISE MA WALD A DEPAOLISJONES A HENRY K WASKIN HA HYSLOP NE MUSHATT DM ZACHARY JA SOEIRO R HARRIS C ZINGMAN B GIORDANO MF SLEDZ S MURRAY HW CAREY JT DAVIS TL BAGBY B KESSLER HA MURPHY RL HIRSCHTICK RE CHEESEMAN SH LAI KK FAIRCHILD PG EHMANN WC ZURLO JJ MILLARD R TROIANI L HEGGEN AA VANDERHORST CM MCKINLEY GF GRIECO MH KOLATCH BR GOLDSMITH JC GOMPERTS ED WOODS LM GRUE L MAYJO K BECKER RL JAYAWEERA DT ROLFE L COLE J JERMANO J
Citation: R. Dolin et al., ZIDOVUDINE COMPARED WITH DIDANOSINE IN PATIENTS WITH ADVANCED HIV TYPE-1 INFECTION AND LITTLE OR NO PREVIOUS EXPERIENCE WITH ZIDOVUDINE, Archives of internal medicine, 155(9), 1995, pp. 961-974
LONG-TERM EFFECTS OF INTERLEUKIN-2 ON CD4 CELL COUNTS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS
Authors: RAMACHANDRAN RV KATZENSTEIN D MERIGAN TC
Citation: Rv. Ramachandran et al., LONG-TERM EFFECTS OF INTERLEUKIN-2 ON CD4 CELL COUNTS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS, The Journal of infectious diseases, 170(4), 1994, pp. 1044-1046
Risultati: 1-25 | 26-27